Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. LakeShore Biopharma Co's cash to debt ratio for the quarter that ended in Mar. 2025 was 0.07.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, LakeShore Biopharma Cocouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.
The historical rank and industry rank for LakeShore Biopharma Co's Cash-to-Debt or its related term are showing as below:
LSBCF's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.56 * Ranked among companies with meaningful Cash-to-Debt only.
LakeShore Biopharma Co (OTCPK:LSBCF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
LakeShore Biopharma Co Cash-to-Debt Related Terms
LakeShore Biopharma Co Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
LSBCF vs ACUT, PPCB, ENSC: Cash-to-Debt Comparison
For the Biotechnology subindustry, LakeShore Biopharma Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LakeShore Biopharma Co (LSBCF) has a Cash-to-Debt of 0.07 as of Mar. 2025.
Is LakeShore Biopharma Co's Cash-to-Debt too high?
LakeShore Biopharma Co's current Cash-to-Debt is 0.07. The Biotechnology industry median Cash-to-Debt is 6.56. LakeShore Biopharma Co's value of 0.07 is 98.9% below this industry median.
How does LakeShore Biopharma Co's Cash-to-Debt compare to ACUT and PPCB?
LakeShore Biopharma Co's Cash-to-Debt of 0.07 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.56. LakeShore Biopharma Co's value of 0.07 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.56, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LakeShore Biopharma Co's current Cash-to-Debt of 0.07 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Cash-to-Debt is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Cash-to-Debt of 0.07. The current Cash-to-Debt is 0.07 and 98.9% below the Biotechnology industry median of 6.56. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Cash-to-Debt is 0.07 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 
